beta-lapachone has been researched along with cryptotanshinone in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
| Hu, Y; Jadhav, P; Tan, B; Tan, H; Wang, J | 1 |
1 review(s) available for beta-lapachone and cryptotanshinone
| Article | Year |
|---|---|
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
Topics: Antiviral Agents; Coronavirus Papain-Like Proteases; COVID-19 Drug Treatment; Humans; Pandemics; Protease Inhibitors; SARS-CoV-2 | 2022 |
2 other study(ies) available for beta-lapachone and cryptotanshinone
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |